| __timestamp | CRISPR Therapeutics AG | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 520990000000 |
| Thursday, January 1, 2015 | 12573000 | 535405000000 |
| Friday, January 1, 2016 | 42238000 | 558755000000 |
| Sunday, January 1, 2017 | 69800000 | 495921000000 |
| Monday, January 1, 2018 | 113773000 | 659690000000 |
| Tuesday, January 1, 2019 | 179362000 | 1089764000000 |
| Wednesday, January 1, 2020 | 269407000 | 994308000000 |
| Friday, January 1, 2021 | 17953000 | 1106846000000 |
| Saturday, January 1, 2022 | 110250000 | 1244072000000 |
| Sunday, January 1, 2023 | 130250000 | 1431505000000 |
| Monday, January 1, 2024 | -2314000 | 1431505000000 |
Unleashing insights
In the ever-evolving landscape of biotechnology, the cost of revenue is a critical metric that reflects a company's operational efficiency. This chart compares the cost of revenue for Takeda Pharmaceutical Company Limited and CRISPR Therapeutics AG from 2014 to 2023. Takeda, a Japanese pharmaceutical titan, consistently reported a cost of revenue exceeding $500 billion annually, peaking at approximately $1.43 trillion in 2023. In contrast, CRISPR Therapeutics, a pioneer in gene-editing technology, showed a more modest trajectory, with costs rising from $1.5 million in 2014 to around $130 million in 2023. This stark contrast highlights the scale and operational differences between a well-established pharmaceutical giant and an innovative biotech startup. Notably, the data for 2024 is incomplete, reflecting the dynamic nature of the industry. This comparison underscores the diverse strategies and challenges faced by companies in the biotech sector.
Cost of Revenue Trends: Eli Lilly and Company vs CRISPR Therapeutics AG
Cost of Revenue Comparison: Pfizer Inc. vs Takeda Pharmaceutical Company Limited
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs CRISPR Therapeutics AG
Cost Insights: Breaking Down Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG's Expenses
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Walgreens Boots Alliance, Inc.
Research and Development Expenses Breakdown: Takeda Pharmaceutical Company Limited vs CRISPR Therapeutics AG
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated
Takeda Pharmaceutical Company Limited vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs CRISPR Therapeutics AG
Cost of Revenue Comparison: Catalent, Inc. vs CRISPR Therapeutics AG
Comparing Cost of Revenue Efficiency: Lantheus Holdings, Inc. vs CRISPR Therapeutics AG
Cost of Revenue: Key Insights for CRISPR Therapeutics AG and HUTCHMED (China) Limited